(COMTEX) B: New Clinical Trial Data Supports Nymox's AlzheimAlert Tes
B: New Clinical Trial Data Supports Nymox's AlzheimAlert Test
MAYWOOD, N.J., Mar 1, 2001 (BW HealthWire) -- Nymox Pharmaceutical Corporation
(NASDAQ: NYMX) announced today the results of a successful large new clinical
trial for its AlzheimAlert(TM) urinary test. The trial was a multi-site
double-blind study involving Alzheimer's disease patients and normal controls.
Overall there were 168 participants in the trial from five institutions.
The new trial found that the AlzheimAlert(TM) test had a sensitivity (percentage
of patients with Alzheimer's disease who tested positive) of over 90% and a
specificity (percentage of normal controls who tested negative) of over 95%.
Dr. Michael Munzar, Medical Director of Nymox, said "This new data has been
carefully scrutinized and provides further verification of the unique value of
this exciting technology. More and more new studies are proving how important
early diagnosis is for the optimal care of patients with Alzheimer's."
AlzheimAlert(TM) is a state of the art test for physicians to aid in the
diagnosis of Alzheimer's disease. The test uses urine samples sent by physicians
to Nymox's clinical reference laboratory in Maywood, New Jersey.
AlzheimAlert(TM) is the latest generation of Nymox's NTP technology which
detects elevated levels of a brain protein (neural thread protein or NTP) known
to be elevated in the urine of patients with Alzheimer's disease.
Nymox is currently marketing its AlzheimAlert(TM) test in the United States
through a medical marketing force of 50 medical representatives.
AlzheimAlert(TM) costs $295.
A bibliography of the extensive scientific literature linking NTP to Alzheimer's
disease and showing its efficacy as a biochemical indicator of the illness is
available at the Nymox website at www.nymox.com. A recent study in the February
issue of the Journal of Neuropathology and Experimental Neurology (Vol. 60,
No.2, pp. 195-207), a prestigious peer-reviewed medical journal, provides new
evidence linking increased production of NTP to the form of programmed cell
death found in the brains of patients with Alzheimer's disease. The results from
the current trial will be presented at a medical meeting later in the year and
will also be published in a peer-review medical journal.
Nymox Pharmaceutical Corporation pioneers in the research and development of
products for the diagnosis and treatment of Alzheimer's disease, an affliction
of more than 15 million people around the world. Nymox offers the world's only
accurate, non-invasive test to aid in the diagnosis of the disease, and is
developing proprietary spheron-based drug therapies that could lead to effective
treatment of Alzheimer's disease. Nymox markets NicAlert(TM), a test that uses
urine or saliva to determine whether a person is using tobacco products. Nymox
is also developing a new class of antibacterial agents for the treatment of
urinary tract and other bacterial infections in humans which have proved highly
resistant to conventional antibiotic treatments and for the treatment of E. coli
0157:H7 bacterial contamination in hamburger meat and other food and drink
products. Under development are a potential saliva-based cholesterol test and a
potential test for osteoporosis. Nymox Pharmaceutical Corporation has facilities
in Montreal and Maywood, NJ. Its stock is traded on NASDAQ with the symbol NYMX.
More information is available at nymox.com.
This press release contains certain "forward-looking statements" as defined in
the United States Private Securities Litigation Reform Act of 1995 that involve
a number of risks and uncertainties. There can be no assurance that such
statements will prove to be accurate and the actual results and future events
could differ materially from management's current expectations. Such factors are
detailed from time to time in Nymox's filings with the United States Securities
and Exchange Commission and other regulatory authorities.
CONTACT: Nymox Pharmaceutical Corporation
Dr. Michael Munzar
1-800-93NYMOX
www.nymox.com
or
Sitrick & Company
Lew Phelps
310-788-2850
URL: businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2001 Business Wire. All rights reserved.
-0-
KEYWORD: NEW JERSEY MARYLAND
INDUSTRY KEYWORD: BIOTECHNOLOGY
MEDICAL
PHARMACEUTICAL
*** end of story *** |
